Clinical Trial Update: The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update evaluating intravenous immunoglobulin therapy for severe pneumonia due to 2019-nCoV (COVID-19) across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2 Infection

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: 2019-nCoV | Phase 2, Phase 3 | Status: UNKNOWN